Matthew M Loar's Net Worth
-$24.7 Thousand
Who is Matthew M Loar?
Matthew M Loar does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include MATEON THERAPEUTICS INC, Transcept Pharmaceuticals Inc, NEUROBIOLOGICAL TECHNOLOGIES INC /CA/, Osteologix, Inc., and GENELABS TECHNOLOGIES INC /CA.
SEC CIK
Matthew M Loar's CIK is 0001236260
Past Insider Trading and Trends
2018 was Matthew M Loar's most active year for acquiring shares with 5 total transactions. Matthew M Loar's most active month to acquire stocks was the month of December. 2003 was Matthew M Loar's most active year for disposing of shares, totalling 1 transactions. Matthew M Loar's most active month to dispose stocks was the month of September. 2017 saw Matthew M Loar paying a total of $131,250.00 for 350,000 shares, this is the most they've acquired in one year. In 2003 Matthew M Loar cashed out on 5,000 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
MATEON THERAPEUTICS INC (OTLC) Snapshot price: $0.03975
Chief Financial OfficerMatthew M Loar owns 300,000 units of Common Stock which is worth $11,925.00. From 2015 to 2018 Matthew M Loar acquired a total of 250,000 shares in MATEON THERAPEUTICS INC.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
| +500.00% | 250K |
—
|
—
| 300K |
Apr 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Transcept Pharmaceuticals Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ No price found
VP and Chief Financial OfficerMatthew M Loar owns 25,000 units of Common Stock. In the year 2008 Matthew M Loar filed a total of 2 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 25K |
$0.75 | $18,750.00 | 25K |
Oct 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Osteologix, Inc. No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GENELABS TECHNOLOGIES INC /CA No price found
CFOMatthew M Loar owns 83,369 units of Common Stock. From 2003 to 2006 Matthew M Loar acquired a total of 19,056 shares in GENELABS TECHNOLOGIES INC /CA at a cost of $17,921.41, Matthew also disposed a total of 5,000 shares of GENELABS TECHNOLOGIES INC /CA.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 27
| |||
Form 4
| +9.12% | 6.13K |
$1.28 | $7,817.03 | 73.37K |
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 23
| |||
Form 4
| +11.43% | 7.92K |
$1.28 | $10,104.38 | 77.24K |
Dec 31
| |||
| No matching records found | |||||||||